Lionco Pharmaceutical Group Co.,Ltd. (SHA:603669)
China · Delayed Price · Currency is CNY 5.29
0.00 (0.00%)
Sep 10, 2026, 3:00 PM CST
SHA:603669 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 393 | 308.87 | 369.53 | 189.31 | 281.79 | 734.89 |
Other Revenue | 15.34 | 13.61 | 10.25 | 7.52 | 7.47 | 5.43 |
| 408.33 | 322.48 | 379.78 | 196.83 | 289.26 | 740.33 | |
Revenue Growth | -0.38% | -15.09% | 92.95% | -31.95% | -60.93% | -26.04% |
Cost of Revenue | 195.27 | 185.12 | 206.52 | 109.88 | 94.53 | 155.71 |
Gross Profit | 213.06 | 137.36 | 173.26 | 86.96 | 194.74 | 584.62 |
Selling, General & Admin | 240.72 | 228.91 | 230.78 | 213.48 | 327.1 | 513.55 |
Research & Development | 11.94 | 12.7 | 26.66 | 29.12 | 31.63 | 22.77 |
Other Operating Expenses | 14.67 | 4.17 | 4.79 | 5.02 | 6.3 | 9.61 |
Operating Expenses | 267.83 | 245.62 | 282.53 | 256.94 | 371.78 | 546.2 |
Operating Income | -54.77 | -108.26 | -109.27 | -169.99 | -177.04 | 38.42 |
Interest Expense | -21.87 | -21.2 | -27.38 | -3.71 | -5.83 | -15.51 |
Interest & Investment Income | 0.12 | 0.24 | 1.29 | 3.31 | 7.11 | 25.31 |
Other Non Operating Income (Expenses) | -42.13 | -41.02 | 26 | -0.81 | -0.31 | -2.41 |
EBT Excluding Unusual Items | -118.66 | -170.24 | -109.35 | -171.2 | -176.08 | 45.81 |
Impairment of Goodwill | - | - | - | - | -2.03 | - |
Gain (Loss) on Sale of Investments | -4.1 | -2.98 | -14.75 | -14.53 | -14.11 | 0.85 |
Gain (Loss) on Sale of Assets | 3.67 | 3.53 | -2.24 | 0.08 | 0.45 | -0.01 |
Asset Writedown | -38.97 | -39.17 | -20.41 | -4.12 | -0.01 | -0.19 |
Other Unusual Items | 21.96 | 15.34 | 19.02 | 38.82 | 2.98 | 24.03 |
Pretax Income | -136.1 | -193.51 | -127.73 | -150.95 | -188.81 | 70.48 |
Income Tax Expense | 0.29 | -0.28 | 3.03 | 0.54 | 7.06 | 4.58 |
Net Income | -136.39 | -193.24 | -130.76 | -151.5 | -195.86 | 65.9 |
Net Income to Common | -136.39 | -193.24 | -130.76 | -151.5 | -195.86 | 65.9 |
Net Income Growth | - | - | - | - | - | -58.83% |
Shares Outstanding (Basic) | 710 | 716 | 726 | 721 | 720 | 718 |
Shares Outstanding (Diluted) | 710 | 716 | 726 | 721 | 720 | 718 |
Shares Change | -4.94% | -1.48% | 0.77% | 0.17% | 0.18% | -5.75% |
EPS (Basic) | -0.19 | -0.27 | -0.18 | -0.21 | -0.27 | 0.09 |
EPS (Diluted) | -0.19 | -0.27 | -0.18 | -0.21 | -0.27 | 0.09 |
EPS Growth | - | - | - | - | - | -57.14% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -111.99 | -135.55 | -119.74 | -61.01 | -109.2 | 73.69 |
Free Cash Flow Per Share | -0.16 | -0.19 | -0.17 | -0.09 | -0.15 | 0.10 |
Dividend Per Share | - | - | - | - | - | 0.100 |
Dividend Growth | - | - | - | - | - | -50.00% |
Gross Margin | 52.18% | 42.59% | 45.62% | 44.18% | 67.32% | 78.97% |
Operating Margin | -13.41% | -33.57% | -28.77% | -86.36% | -61.20% | 5.19% |
Profit Margin | -33.40% | -59.92% | -34.43% | -76.97% | -67.71% | 8.90% |
Free Cash Flow Margin | -27.43% | -42.03% | -31.53% | -30.99% | -37.75% | 9.95% |
EBITDA | -29.45 | -82.11 | -75.27 | -125.93 | -134.37 | 77.83 |
EBITDA Margin | -7.21% | -25.46% | -19.82% | -63.98% | -46.45% | 10.51% |
D&A For EBITDA | 25.32 | 26.14 | 34 | 44.05 | 42.67 | 39.41 |
EBIT | -54.77 | -108.26 | -109.27 | -169.99 | -177.04 | 38.42 |
EBIT Margin | -13.41% | -33.57% | -28.77% | -86.36% | -61.20% | 5.19% |
Effective Tax Rate | - | - | - | - | - | 6.49% |
Revenue as Reported | 408.33 | 322.48 | 379.78 | 196.83 | 289.26 | 740.33 |